At the heart of our drug development process is our in-silico platform – Hyper-C. Over 70 man-years of development have gone into creating a revolutionary platform that efficiently identifies undetected relationships between drug candidates and diseases at the chemical compound level.
Hyper-C achieves this through an iterative process where immense quantities of data from 15+ major data stores including biomedical literature, molecular modeling, clinical studies, investigations, clinical trials, etc. are analyzed against disease models. Utilizing its algorithmic intelligence Hyper-C efficiently identifies relationships between drugs and diseases. The result is a proposed shortlist of potential drug candidates that have survived countless rounds of in-silico testing.
Many other AI-enabled drug discovery platforms are akin to a black box in that the result(s) are not always understandable. Hyper-C provides a clear mechanism of action hypothesis and biomarkers for patient stratification. This allows our team to quickly work with and interpret the data. It also has the added benefit of making it easier to satisfy regulatory requirements.